Relative to routine stenting, drug-eluting balloon revascularization with as-needed stenting produced similarly low target ...
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
Recent findings from a substudy of DETOUR2 demonstrated that percutaneous transmural arterial bypass (PTAB) may offer an ...
BASKING RIDGE, N.J. -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters ...
Please provide your email address to receive an email when new articles are posted on . In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...
DURHAM, N.C.--(BUSINESS WIRE)--Istari Oncology, Inc., a clinical-stage biotechnology company focused on development of the novel immune activator lerapolturev for the treatment of solid tumors, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results